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Abstract
Purpose Matrix metalloproteinases (MMPs) are identified as modulators of the extracellular matrix in heart failure progression.
However, evidence for intracellular effects of MMPs is emerging. Pro- and anti-hypertrophic cardiac effects are described. This may
be due to the various sources of differentMMPs in the heart tissue. Therefore, the aim of the present studywas to determine the role of
MMPs in hypertrophic growth of isolated rat ventricular cardiac myocytes.
Methods Cardiomyocytes were isolated form ventricular tissues of the rat hearts by collagenase perfusion. RT-qPCR, western
blots, and zymography were used for expression andMMP activity analysis. Cross-sectional area and the rate of protein synthesis
were determined as parameters for hypertrophic growth.
Results MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 mRNAs were detected in cardiomyocytes, and protein expression of
MMP-2, MMP-9, and MMP-14 was identified. Hypertrophic stimulation of cardiomyocytes did not enhance, but interestingly
decreased expression of MMPs, indicating that downregulation of MMPs may promote hypertrophic growth. Indeed, the
nonselective MMP inhibitors TAPI-0 or TIMP2 and the MMP-2-selective ARP-100 enhanced hypertrophic growth.
Furthermore, TAPI-0 increased phosphorylation and thus activation of extracellular signaling kinase (ERK) and Akt (protein
kinase B), as well as inhibition of glycogen synthase 3β (GSK3β). Abrogation of MEK/ERK- or phosphatidylinositol-3-
kinase(PI3K)/Akt/GSK3β-signaling with PD98059 or LY290042, respectively, inhibited hypertrophic growth under TAPI-0.
Conclusion MMPs’ inhibition promotes hypertrophic growth in cardiomyocytes in vitro. Therefore, MMPs in the healthy heart
may be important players to repress cardiac hypertrophy.
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Introduction
Heart failure is one of the major causes of death in industrial
countries and cardiac hypertrophy is a prerequisite of heart fail-
ure development. Cardiac hypertrophy is amultifactorial disease
that can be caused by enlargement of the cardiomyocytes them-
selves. But also proliferation of cardiac fibroblasts [1] or the
assembly of amyloid fibrils in the extracellular space [2] con-
tribute to the enlargement of the heart, stiffening of the wall
chambers, and finally impaired cardiac function.
Many therapeutics have been defined already in order to
treat cardiac hypertrophy and to prevent heart failure progres-
sion, i.e., inhibitors of the renin-angiotensin system or calcium
channel blockers. However, not all patients respond to these
drugs, or only to a limited extent [3]. Therefore, identification
of new therapeutic targets in the treatment of cardiac hyper-
trophy is urgently needed. In this study, we focus on the role
of matrix metalloproteinases (MMPs) in cardiac hypertrophy.
During cardiac remodeling, processes that include cardiac
hypertrophy and restructuring of the extracellular matrix are
induced. MMPs are found activated and involved in cardiac
remodeling. Primarily, these enzymes were described to
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degrade the extracellular matrix and, thereby, contribute to
matrix remodeling. However, recent research demonstrated
induction of intracellular processes in cardiomyocytes by
MMPs, either due to proteolytical processes at diverse cell
surface ligands, receptors, or signaling molecules, or inside
the cell, sinceMMPs are not only restricted to the extracellular
matrix but are also active inside the cardiomyocytes [4].
Going along with these findings, an increasing number of
substrates that can be targeted by MMPs are defined, and the
role of MMPs in diverse processes of cardiac remodeling is
steadily increasing. Numerous studies demonstrate the influ-
ence of MMPs on cardiac hypertrophy, although with differ-
ent outcomes [5–8], e.g., reduction or induction of cardiac
hypertrophy by MMPs. Since most of these studies were con-
ducted in in vivo animal models, often in transgenic mice, the
divergent outcomes may be due to the complexity of MMP
functions in different cell types.
Currently, around 30 MMP members are known. They are
proteolytic enzymes that are synthesized as inactive pro-forms
which are activated upon their release from different cell types
into the extracellular matrix [9]. Also in the heart, the role of
MMPs was primarily described to enhance extracellular matrix
degradation and fibrosis, i.e., in ischemic-reperfused myocardi-
um [10, 11] or in myocarditis [12]. However, the spectrum of
cardiac MMP targets is currently expanding. Under angiotensin
II (AngII) infusion in MMP-2 knockout mice, cardiac hypertro-
phy progressed earlier and with greater severity, thereby indi-
cating a protective role of MMP-2 in progression of cardiac
hypertrophy [5]. Others identified MMP-7 as a mediator of hy-
pertrophy under AngII infusion [6]. Furthermore, macrophage-
specific overexpression of MMP-9 in transgenic mice enhanced
cardiac hypertrophy [7]. These findings indicate the complex
intercellular interaction of MMPs. In addition to MMPs,
ADAMs (A disintegrin and metalloproteinases), which are
closely related to the MMP family, have pro- and anti-
hypertrophic actions [13]. Both, MMPs and ADAMs, can influ-
ence hypertrophic signaling cascades like Akt (protein kinase B)
or ERK (extracellular signal-regulated kinase) via extracellular
cleavage of cell surface integrins or receptors.
The current study focused on MMP effects on
cardiomyocytes independent of other cell types in the heart.
We analyzed the expression patterns of MMPs in isolated
ventricular cardiomyocytes of adult rat and demonstrate pro-
hypertrophic effects under MMP inhibition. With this, we
identifiedMMPs as repressors of cardiomyocyte hypertrophy.
Materials and Methods
Materials
Medium 199 was obtained from Boehringer (Mannheim,
Germany), fetal calf serum from PAA (Linz, Austria), crude
collagenase from Biochrom (Berlin, Germany), and MMP
inhibitors from Merck (Darmstadt, Germany). Antibodies for
MMP-2, MMP-9, and MMP-14 and integrin1β were from
Abcam, antibodies against ERK and p-ERK were from
Santa Cruz (Heidelberg, Germany) and against p-GSK3β
were from Cell Signaling (Frankfurt, Germany), and vinculin
antibodies were from Sigma-Aldrich (Taufkirchen,
Germany). Secondary antibodies were from Cell Signaling
(Frankfurt, Germany). GSK-3β Activity Assay Kit was from
Sigma.
Cell Isolation and Cardiomyocyte Cultures
Ventricular cardiomyocytes were isolated from 200 to 250 g
maleWistar rats, suspended in basal culture medium and plat-
ed on culture dishes, which were preincubated overnight with
4% fetal calf serum in medium 199, as previously described
[14]. The basal culture medium (CCT) was modified medium
199 including Earle’s salts, 2 mM L-carnitine, 5 mM taurine,
100 IU/ml penicillin, 100 μg/ml streptomycin, and 10 μM
cytosine-β-D-arabinofuranoside (pH 7.4). Three hours after
plating, the dishes were washed twice with CCT medium.
This results in cultures of about 90% quiescent rod-shaped
cells on average. Cardiomyocytes were treated as depicted in
Fig. 1.
Cardiac Specimens from Spontaneous Hypertensive
Rats
Cardiac specimens originate from a study published by
Schreckenberg et al. [15]. Female SHR rats and normotensive
Wistar rats were kept over 7.5 months. At the age of 1.5 and
7.5 months, blood pressure was determined by tail-cuff mea-
surements. At the end of the experimental period, rats were
anesthetized by isoflurane inhalation. After cervical disloca-
tion, the hearts were isolated and perfused in Langendorff
technique to remove blood contamination. Heart weight to
tibia length was determined as parameter of cardiac hypertro-
phy. The hears were frozen in liquid nitrogen and stored at −
80 °C.
Real-Time RT-PCR
Total RNA from cardiomyocytes was extracted with Trizol
(Invitrogen) as described by the manufacturer. This was
followed by DNAse treatment and reverse transcription with
QuantiTect Reverse Transcription Kit from Qiagen. For each
assayed gene, annealing temperature and the number of cycles
resulting in a linear amplification range were tested. RT-PCR
was performed in an automated thermal cycler and detected
with the Bio-Rad detection system (Bio-Rad) using SYBR
Green fluorescence for quantification. The calculations of
the results were carried out according to the 2−ΔΔCt methods
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as described [16]. Gene expression was related to β2-
microglobulin (B2M) as housekeeping gene. Primer se-
quences are listed in Table 1.
Immunoblotting
At the end of the treatment, cells were washed twice with ice-
cold phosphate-buffered saline (PBS) before being lyzed on
ice in RIPA buffer [50 mmol/L Tris/HCl, pH 7.5, 150 mmol/L
NaCl, 1% Nonidet P-40, 0.5% deoxycholat, 0.1% sodium
dodecylsulfate (SDS)] containing protease inhibitor
[1 mmol/L phenylmethylsulfonylfluoride (PMSF), 1 mmol/L
ethylenediaminetetraacetic acid (EDTA), 1 mg/L pepstatin].
The protein content was determined by Lowry protein assay
[17]. For control, every blot was stained with Ponceau Red
before blotting. Primary antibodies were used according to the
manufacturer’s instructions. Protein bands were detected by
horseradish peroxidase-labeled anti-rabbit antibodies by the
use of the ECL detection system. Vinculin was used for load-
ing controls.
Zymography Assay
Gelatinolytic activity of MMP was examined as previously
described in detail [18, 19]. Briefly, 8% polyacrylamide gels,
co-polymerized with gelatin (2 mg/ml), were loaded with
50μg of protein. After electrophoresis, gels were washed with
renaturation buffer (containing 2.5% Triton X-100), and then
Fig. 1 Study design and
treatment protocol.
Cardiomyocytes were treated
with hypertrophic growth stimuli
(indicated in green) for 24 h in
order to determine MMP
expression under these stimuli. In
another set of experiments,
cardiomyocytes were treated with
MMP inhibitors (indicated in red)
for 24 h in order to determine their
influence on hypertrophic growth.
In addition, inhibition of MMP
activity was proved in
zymography assays. Finally,
phosphorylation of kinases,
typically related to hypertrophic
growth (ERK, Akt, and GSK3β),
was determined under MMP
inhibition with TAPI-0 within
5 min to 2 h, and the influence of
ERK or PI3K inhibition on TAPI-
0 induced hypertrophic growth
was determined
Table 1 Primer sequences for














Primers are listed in 5′ to 3′ direction
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incubated in development buffer to eliminate Triton X-100.
Gels were stained with 0.05% Coomassie Brilliant Blue, and
gelatinolytic activities were detected as transparent bands
against the dark-blue background. Band intensities were quan-
tified (Quantity One software, Bio-Rad, Hercules, CA) and
expressed in arbitrary units.
Incorporation of 14C-Phenylalanine
To determine the rate of protein synthesis, incorporation of
phenylalanine was measured by exposing cultures to L-14C-
phenylalanine (0.1 μCi/ml) for 24 h. Incorporation of radio-
activity into acid-insoluble cell mass was determined as de-
scribed before [20].
Cross-Sectional Area
The cardiomyocyte size was determined on micrographs dig-
italized by a charge-coupled device camera, as described else-
where [21]. Five micrographs were taken randomly per sam-
ple, and all rod-shaped myocytes in these fields were mea-
sured. A total of about 30 cells were measured for one condi-
t ion in one prepara t ion . The width /d iameter of
cardiomyocytes was determined at the widest point of each
cardiomyocyte using the software program Analysis from
SIS. The cross-sectional area of cardiomyocytes was calculat-
ed by the following formula: (radius)2 × π.
Determination of GSK-3β Activity
The GSK-3β activity was determined by the use of GSK3β
activity assay kit from Sigma. The total protein was extracted
as described for immunoblots. Then GSK3β was
immunoprecipitated. After addition of a peptide substrate
and γP32-ATP, labeling of the peptide by GSK-3β was
determined.
Statistics
Data are given as mean ± standard deviation from n different
animals. Statistical comparisons were performed by ANOVA
(one-way or two-way analysis of variance) and Student-
Newman-Keuls test or Student t test. A p value of less than
0.05 was considered statistically significant.
Results
Expression of MMPs in Cardiomyocytes
As reviewed by Spinale [22], eight differentMMPswere iden-
tified in the whole myocardium, namely, MMP-1, MMP-2,
MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, and MMP-
14. We now analyzed mRNA expression of these MMPs on
the cellular level in isolated adult rat cardiac myocytes. As
depicted in Fig. 2A, reproducible and clear bands were detect-
ed for MMP-1, MMP-2, MMP-3, MMP-9, and MMP-14,
thereby indicating that these MMPs are expressed in
cardiomyocytes under basal culture conditions. A weak and
non-reproducible mRNA expression was found for MMP-8
and MMP-13, whereas the expression of MMP-7 was not
detected at all.
To determine if this pattern of MMP mRNA expres-
sion changes under hypertrophic growth stimulation,
ca rd iomyocy te s were s t imu la t ed wi th the α -
adrenoceptor agonist phenylephrine (PE, 10 μM), with
transforming growth factor β1 (TGFβ1, 1 ng/ml), or
angiotensin II (AngII, 100 nM) for 24 h. PE and
AngII treatments lead to well-known pro-hypertrophic
effects in cardiomyocytes [23–26], whereas TGFβ1 is
known to induce hypertrophic responsibili ty in
cardiomyocytes and cardiac remodeling in the heart
[27, 28]. Interestingly, MMP upregulation was not
found under hypertrophic growth stimulation. Instead,
some MMP mRNAs were downregulated under pro-
hypertrophic conditions: PE reduced MMP-9 mRNA to
0.56 ± 0.36 times of control, and MMP-14 mRNA to
0.48 ± 0.15 times of control (n = 8, p < 0.05). AngII
stimulation reduced the level of MMP-1 mRNA to
0.29 ± 0.28 times of control and MMP-14 mRNA to
0.50 ± 0.20 times of control (n = 7 – 8, p < 0.05).
TGFβ1 reduced mRNA expression of MMP-9 to 0.52
± 0.25 times of control (n = 8, p < 0.05) (Fig. 2B).
Furthermore, we tested if reduced MMP mRNA expres-
sions under hypertrophic stimulation are reflected on the pro-
tein levels. Therefore, cardiomyocytes were again stimulated
with PE, AngII, and TGFβ1. As depicted in Fig. 3A, protein
expressions ofMMP-2, with a main band at 68 kDa, ofMMP-
9 (at 92 kDa), and MMP-14 (around 50 kDa) were detected.
Quantification of Western blots revealed no significant upreg-
ulation of MMPs. However, MMP-9 expression declined un-
der stimulation with PE or AngII (Fig. 3B).
In order to assess whether MMP downregulation can
be observed in vivo, too, we analyzed MMP-2 and
MMP-9 mRNA expression in spontaneous hypertensive
rats (SHR). As published earlier, these animals are pre-
hypertensive in the age of 1.5 months but develop a
manifest high blood pressure at the age of 7.5 months,
which goes along with cardiac hypertrophy, as deter-
mined by heart weight/tibia length (data published in
[15]). The MMP mRNA expression in specimens of
these animals revealed a decline in MMP-9 mRNA ex-
pression in 7.5-month-old SHR rats to 42 ± 15% com-
pared to age-matched normotensive Wistar rats (n = 6,
p < 0.05) (Fig. 4). MMP-2 mRNA levels remained un-
changed (data not shown).
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Fig. 2 MMP mRNA expression in cardiomyocytes. (A) Total RNA was
isolated from ventricular cardiomyocytes, RT-PCR performed, and am-
plification products were loaded on agarose gels (n = 4 independent cul-
ture preparations). mRNA expression ofMMP types1, 2, 3, 9, and 14was
detected (indicated by arrows). (B) To determine the changes in mRNA
expression under hypertrophic growth stimulation, cardiomyocytes were
incubated for 24 h with phenylephrine (PE, 10 μM), TGFβ1 (1 ng/ml), or
angiotensin II (Ang, 100 nM). mRNA expression of MMP types was
analyzed by real-time RT-PCR (n = 7 – 9, *p < 0.05 vs. controls)
Fig. 3 MMP protein expression
under hypertrophic growth
stimulation. Cardiomyocytes
were incubated for 24 h with
phenylephrine (PE, 10 μM),
TGFβ1 (1 ng/ml), or angiotensin
II (Ang, 100 nM). Protein
expression of MMP-2, MMP-9,
andMMP-14 could be detected in
(A) Western blots, and (B) bands
were densiometrically evaluated.
Vinculin expression served as
loading control. (n = 7 – 11,
*p < 0.05 vs. controls)
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MMP Inhibition Enhances Hypertrophic Growth of
Cardiac Myocytes
The finding that MMP expression in cardiac myocytes is rath-
er down- than upregulated under hypertrophic growth stimu-
lation suggested that MMP attenuation might be involved in
the process of hypertrophic growth. Hence, we tested the ef-
fect of different MMP inhibitors on hypertrophic growth. We
used three different kinds of MMP inhibitors: TAPI-0 as a
nonselective pharmacologic inhibitor known to inhibit
MMP-1, MMP-2, MMP-8, MMP-9, MMP-13, and MMP-
18; recombinant human tissue inhibitors of metalloproteinases
type 2 (TIMP2), which also has a broad spectrum of MMP
inhibition; and ARP-100 as a more specific pharmacological
inhibitor of MMP-2. Reduction of the gelatinolytic activity of
MMPs by the pharmacological inhibitors TAPI-0 and ARP-
100 was verified in zymography assays (Fig.5). As depicted,
TAPI-0 reduced total gelatinolytic activity to 70.0 ± 24.2%
(n = 6, p < 0.05), and ARP-100 to 77.4 ± 24.4% compared to
controls (n = 11, p < 0.05) (Fig. 5B).
Then, the effects of the inhibitors on cardiac myocytes
hypertrophy were tested. Addition of 50 μM TAPI-0 to car-
diac myocytes for 24 h increased the rate of protein synthesis
to 128.9 ± 6.8% (n = 17, p < 0.05 vs. control) (Fig. 6) and an
increase in cross-sectional area of the cardiomyocytes up to
125.6 ± 4.4% was found (297 cells in n = 10, p < 0.05 vs.
control) (Fig. 6). Since TAPI-0 is also known as an inhibitor
of TNFα-convertase, we used the TNFα antagonist WP9QY
to exclude that the effects of TAPI-0 were due to the inhibition
of TNFα signaling. Incubation of cardiomyocytes with
WP9QY (25 μM) for 24 h did not enhance the rate of protein
synthesis (102.8 ± 3.0%, n = 6, n.s. vs. control). Incubation of
cardiac myocytes with the TIMP2 (24 mM) for 24 h increased
the rate of protein synthesis to 124.3 ± 8.4% (n = 11, p < 0.05
vs. control) and cross-sectional area to 117.2 ± 3.3% (246 cells
in n = 7, p < 0.05 vs. control) (Fig. 6). Furthermore, ARP-100
(50 nM) enhanced the rate of protein synthesis to 131.4 ±
10.0% (n = 4, p < 0.05), and the cross-sectional area of cardiac
myocytes to 111.4 ± 4.2% (277 cells in n = 7, p < 0.05) (Fig.
6). Thus, independent of the specificity of the MMP inhibitor,
reduction of MMP activity in cardiac myocytes provoked hy-
pertrophic growth.
Hypertrophic Signaling Under MMP Inhibition
To analyze if extracellular matrix modifications have contrib-
uted the hypertrophic growth responses under MMP inhibi-
tion, we determined integrin1β expression under TAPI-0 or
ARP-100. However, integrin1β expression did not change,
neither on the mRNA nor on the protein level (mRNA: 1.01
± 0.4 times under TAPI-0 and 1.04 ± 0.5 times under ARP-
100, n = 7, n.s. vs. control; and protein: 99 ± 33% under TAPI-
0, and 119 ± 56 under ARP-100, n = 7, n.s. vs. control).
Cardiac hypertrophy can be induced by diverse factors and
conditions that ultimately converge on a limited number of
protein kinases. Among others, ERK, PI3K (phos-
phatidylinositol-3-kinase), and Akt are prominent kinases,
most often found to be involved in hypertrophic signaling
[29]. Therefore, we tested the involvement of these kinases
in hypertrophic growth stimulation followingMMP inhibition
by TAPI-0.
As a sign for ERK activation, phosphorylation of ERKwas
determined in Western blots. After addition of TAPI-0, ERK
activation was visible within 5 min. A significant enhance-
ment to 238.9 ± 38.4% was detected after 30 min (n = 7, p <
0.05 vs. control). Thereafter, ERK activity declined to base-
line levels (Fig. 7A). Involvement of ERK in TAPI-0-induced
hypertrophy was determined by the inhibition of ERK signal-
ing with 10 μM PD98059, which is a highly selective inhib-
itor of MEK1 and the MAP kinase cascade. ERK inhibition
abolished TAPI-0-induced hypertrophic growth, since cell
size did not increase under TAPI-0 in the presence of
PD98059 (100.8 ± 4.3%, n = 6, p < 0.05 vs. TAPI-0 stimula-
tion) (Fig. 7B). PD98059 per se did not modify cross-sectional
area.
As indicator for activation of PI3K/Akt-signaling, phos-
phorylation of Akt was detected in Western blots within
15 min after addition of TAPI-0 (Fig. 8A). Incubation of
Fig. 4 MMP mRNA expression in SHR rats. Total RNA was isolated
from the hearts of pre-hypertensive 1.5-month-old and hypertensive 7.5-
month-old SHR rats, as well as from age-matched normotensive Wistar
rats. mRNA expression of MMP-9 was analyzed by real-time RT-PCR
(n = 5 – 6, *p < 0.05 vs. normotensive Wistar rats)
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cardiac myocytes with LY290042 (10 μM) for 30 min prior to
TAPI-0 stimulation reduced the hypertrophic growth re-
sponse. The cross-sectional area of cardiomyocytes under
TAPI-0 stimulation did not increase in the presence of
LY290042 (113.7 ± 3.6%, n = 10, p < 0.05 vs. TAPI-0 stim-
ulation, n.s. vs. control) (Fig. 8B). LY290042 per se did not
modify the cross-sectional area.
A classical downstream target of PI3K in hypertrophic sig-
naling is the inhibition of GSK3β (glycogen synthase3 β).
GSK3β is constitutively expressed in cardiac myocytes and
was among the first negative regulators of cardiac hypertrophy
to be identified [30, 31]. Similarly, here we identified MMPs
as negative regulators of cardiomyocytes growth. We now
analyzed if inhibition of MMPs may also inactivate GSK3β
and if it may promote hypertrophic growth via this pathway.
Indeed, Ser9 phosphorylation of GSK3β, which is a sign of
GSK3β inactivation, was enhanced after addition of TAPI-0.
Phosphorylation at Ser9 reached a maximum 60 min after
addition of TAPI-0 (236.7 ± 33.1%, n = 9, p < 0.05 vs. con-
trol) (Fig. 9A). To confirm these findings of GSK3β inactiva-
t i o n u n d e r MMP i n h i b i t i o n , t h e a c t i v i t y o f
immunoprecipitated GSK3β was determined by incorpora-
tion of 32P in a substrate peptide in vitro. One hour after
addition of TAPI-0, a reduction of GSK3β activity to 62.3 ±
4.2% was detected (n = 3, p < 0.05 vs. control) (Fig. 9B). The
addition of the GSK3β inhibitor SB415286 to the kinase
Fig. 5 Pharmacologic inhibition
of MMP activity.
Cardiomyocytes were incubated
with phenylephrine (PE, 10 μM),
ARP-100 (50 nM), or TAPI-0
(50 μM) for 24 h. Then, MMP
activity was determined by
zymography. (A) Representative
zymogram. (B) Densiometric
evaluation ofMMP activity (n = 6
for PE, n = 11 for ARP-100, n = 6
for TAPI-0, p < 0.05 vs. control)
Fig. 6 MMP inhibitors enhance
hypertrophic growth.
Cardiomyocytes were incubated
with the MMP inhibitors TAPI-0
(50 μM), TIMP2 (24 mM), and
ARP-100 (50 nM) for 24 h. For
detection of hypertrophic growth,
incorporation of 14C-phenylala-
nine during 24 h, or cross-
sectional area, was determined
after 24 h. Data are expressed as
percent increase relative to un-
treated controls and are means ±
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reaction abolished GSK3β activity. As well, GSK3β activity
was absent when immunoprecipitation was performed in the
absence of GSK3β antibodies. These controls confirm the
specificity of the GSK3β activity assay.
Discussion
The main finding of the study is the identification ofMMPs as
repressors of hypertrophic growth in cardiomyocytes. This
could be demonstrated by the enhancement of the rate of pro-
tein synthesis and of cardiomyocytes’ size under nonspecific
inhibition of MMPs and inhibition of MMP-2.
As could be shown in PCR and Western blots, different
MMP types are expressed in isolated cardiomyocytes of adult
rat, namely, MMP-1, MMP-2, MMP-3, MMP-9, and MMP-
14. Of these transcripts, only MMP-2, MMP-9, and MMP-14
are sufficiently translated into proteins, so that they were de-
tected by Western blot. The reasons for non-detection of
MMP-1 and MMP-3 on the protein level may be a non-
efficient translation of the mRNA or a strong secretion of
these MMP types into the medium so that they cannot be
detected in protein extracts of the cardiomyocytes.
Furthermore, as we did not use a positive control in Western
blots, we cannot completely exclude that the antibodies were
working insufficiently. In spite of this limitation, we can con-
clude that the expression profile of MMPs in cardiomyocytes
is clearly reduced compared to the MMP types found in myo-
cardium (reviewed by Spinale [22]), thereby indicating that
other cell types in the heart, like endothelial cells or fibro-
blasts, are the source of the greater MMP diversity in the
myocardium.
Interestingly, we did not observe any stimulation of MMPs
under pro-hypertrophic treatment. However, mRNA down-
regulation of MMP-1, MMP-9, or MMP-14 under stimulation
of cardiomyocyte hypertrophy by phenylephrine or AngII, as
well as under TGFβ1 stimulation, was detected, and MMP-9
was reduced by phenylephrine and AngII. Different subsets of
MMPs were downregulated by each of the hypertrophic stim-
uli. Reasons for this may rely on the different receptors that
t ransfer the hyper t rophic s t imulus into the cel l
(adrenoreceptor, AT1-receptor, or TGFβ receptor), which
are coupled to diverse signaling cascades. For example, the
TGFβ1 receptor is tightly coupled to transcription factors of
Fig. 7 Hypertrophic growth under MMP inhibition is mediated by ERK.
Cardiomyocytes were stimulated with TAPI-0 (50 μM) for 24 h. For
inhibition of ERK, PD98059 (PD, 10 μM) was added 30 min before
TAPI-0. (A) For detection of phosphorylated and, thus, activated ERK,
cardiomyocytes were stimulated with TAPI-0 (50 ng/ml) for 5 min up to
2 h. Total protein extracts were prepared, separated on 10% SDS gels.
ERK activation was determined in Western blots by determination of p-
ERK/ERK levels. Data are expressed as percent increase relative to
untreated controls and are means ± SE of seven independent culture
preparations. *Differences from unstimulated controls with p < 0.05.
(B) For detection of hypertrophic growth, an increase in cross-sectional
area during 24 h was determined. Data are expressed as percent increase
relative to untreated controls and are means ± SE of six independent
culture preparations. *Differences from unstimulated controls with
p < 0.05. #Differences from TAPI-0 stimulated cells with p < 0.05
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Fig. 9 MMP inhibition reduces GSK3β phosphorylation and activity.
(A) Cardiomyocytes were stimulated with TAPI-0 (50 ng/ml) for 5 min
up to 2 h. Total cell extracts were prepared and separated on 10% SDS
gels. GSK3β activation was determined inWestern blots using antibodies
specific for P-serine9-GSK3β. Data are expressed as percent increase
relative to untreated controls and are means ± SE of nine independent
culture preparations. *Differences from unstimulated controls with
p < 0.05. (B) Cardiomyocytes were stimulated with TAPI-0 (50 ng/ml)
for 1 h. Tota l ce l l ext rac ts were prepared, GSK3β was
immunoprecipitated, and phosphorylation of GSK3β substrate peptide
was determined in vitro. Controls for GSK3β specificity were done either
by addition of the GSK3β inhibitor SB 415286 (SB) to the kinase reac-
tion or by omission of GSK3β antibodies (AB) during immunoprecipi-
tation. Data are expressed as percent increase relative to untreated con-
trols and are means ± SE of three independent culture preparations.
*Differences from unstimulated controls with p < 0.05. **Differences
from unstimulated controls with p < 0.01
Fig. 8 Hypertrophic growth
under MMP inhibition is
mediated by PI3K.
Cardiomyocytes were stimulated
with TAPI-0 (50 μM) for 24 h.
For inhibition of PI3K,
LY290042 (LY, 10 μM) was
added 30 min before TAPI-0. (A)
For detection of phosphorylated
and thus activated PI3K,
cardiomyocytes were stimulated
with TAPI-0 (50 ng/ml) for 5 min
up to 2 h. Total cell extracts were
prepared and separated on 10%
SDS-gels. PI3K activation was
determined in Western blots by
determination of p-PI3K. (B) For
detection of hypertrophic growth,
an increase in cross-sectional area
during 24 h was determined. Data
are expressed as percent increase
relative to untreated controls and
are means ± SE of n = 4–10 in-
dependent culture preparations.
*Differences from unstimulated
controls with p < 0.05.
#Differences from TAPI-0 stimu-
lated cells with p < 0.05
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the SMAD family [32], while phenylephrine signals via basic
leucine zipper (bZIP) family of transcription factors, like AP-1
[33], thereby conveying different promotor specificities. In
hypertensive SHR rats which developed cardiac hypertrophy,
we also observed downregulation of MMP-9 mRNA while
MMP-2 mRNA was preserved. This fits quite well to our
observation thatMMP-9 is downregulated under adrenoceptor
stimulation in cardiomyocytes. In contrast to our observations
of downregulation of MMPs, in animal models with induction
of cardiac hypertrophy, MMPs are often found to be upregu-
lated, i.e., under AngII infusion, induction of MMP-7 was
shown [34]; under norepinephrine infusion [35] or pressure
overload [8], MMP-2 was induced. In MMP-2 knockout mice
cardiac hypertrophy under pressure overload was repressed
[8]. There are several reasons that may contribute to these
differences: (1) regulation of MMPs may be stimulus depen-
dent, (2) time dependent, (3) MMP-type dependent, and (4)
source dependent. The sources of MMPs in animal studies
were not determined and might be different from
cardiomyocytes. The release of MMPs by, e.g., fibroblasts
may preferably contribute to extracellular matrix remodeling
and fibroblast proliferation, which then is a trigger for hyper-
trophic growth. Furthermore, in the heart, mechanical stress
may, in addition to the stimuli used in our in vitro study,
influence MMP expression [36]. Thus, we clearly have to
distinguish between the anti-hypertrophic action of MMPs in
cardiomyocytes and pro-hypertrophic actions by extracellular
matrix remodeling of heart tissue. In future studies, co-culture
systems should be applied in order to analyze the mutual in-
fluence of cardiomyocytes and fibroblasts.
Downregulation of MMPs under hypertrophic growth
stimulation in cardiomyocytes indicated that MMP downreg-
ulation could be functionally involved in the hypertrophic
growth process of cardiomyocytes. Indeed, we show that
MMP inhibitors induce hypertrophic growth in isolated
cardiomyocytes, independent of other additional hypertrophic
stimuli. This indicates that the presence of MMPs under base-
l ine condi t ions reduces hyper t rophic growth of
cardiomyocytes. These findings are similar to the induction
of left ventricular hypertrophy in EMMPRIN knockout mice
[37]. EMMPRIN is an endogenous stimulator of MMPs. In
EMMPRIN knockout mice, reduced MMP-1 and MT1-MMP
levels were found. Aberrant extracellular matrix remodeling
occurred in these animals that contributed to ventricular hy-
pertrophy. If cardiomyocyte growth was also involved in the
hypertrophic growth process, it was not analyzed in that study.
However, since we did not detect MMP-1 in cardiomyocytes,
the development of cardiac hypertrophy in EMMPRIN
knockout mice might differ from that in isolated
cardiomyocytes.
In our study, MMP inhibitors with a nonselective MMP
inhibition (TAPI-0 and TIMP2) were used, so that we cannot
attribute the anti-hypertrophic role to one specific MMP type.
But in zymography, efficient repression of MMP activity by
TAPI-0 was proven. Furthermore, the more specific MMP-2
inhibitor ARP-100 also induced hypertrophic growth, thereby
indicating that MMP-2 is at least one of the anti-hypertrophic
MMPs found in cardiomyocytes. ARP-100 was used as
MMP-2 specific inhibitor already in other studies on heart
disease: in isolated hearts, ARP-100 reduced ischemia-
reperfusion injury via protection against junctophilin 2 or
SERCA (Sarcoplasmic reticulum calcium ATPase) degrada-
tion [38, 39]. Thus, ARP-100 promotes cardiomyocyte hyper-
trophy but prevents contractile dysfunction in ischemic reper-
fused myocardium. These divergent findings imply protective
as well as detrimental roles of MMP-2 in the heart.
The reduction of only 20–30% ofMMP activity by TAPI-0
or ARP-100 affects signaling and promotes phenotypic
changes in cells. However, given the fact that nonselective
pharmacological inhibitors were used in the present study,
we are unable to draw solid conclusions on the MMPs in-
volved in our findings. In future studies, more specific and
efficient inhibition of MMPs, e.g., via siRNA approaches,
should be applied in order to shed light on the multiple func-
tions of MMPs in cardiomyocytes.
Other studies that revealed anti-hypertrophic actions of
MMPs were in vivo studies in mice under hemodynamic
stress, induced either byAngII infusion or transaortic constric-
tion (TAC). In ADAM22 [40], as well as in ADAM12 knock-
out mice [41], cardiac hypertrophy was aggravated under
pressure overload. In both knockout animals, enhancement
of ERK or Akt signaling was seen that may have contributed
to cardiac hypertrophy. Also in our study, we observe activa-
tion of ERK and Akt under MMP inhibition. By the use of
specific inhibitors against ERK and PI3K, which is a direct
activator of Akt [42], we now demonstrate the involvement of
these kinases in hypertrophic growth under MMP inhibition.
Our data imply that also in ADAM22 and 12, ERK/Akt sig-
naling may be involved in the hypertrophic growth process.
Mechanistically, Akt1 directly promotes protein transla-
tion, in part by inhibiting GSK3β activity, which negatively
regulates eukaryotic translation initiation factor 2B and there-
by represses cardiac hypertrophy [30]. In our study, we pres-
ent evidence that MMP inhibition represses GSK3β activity
in cardiomyocytes. Therefore, via inhibition of the repressor
function of GSK3β, MMP inhibition might promote the hy-
pertrophic growth response in cardiomyocytes.
Thus, induction of intracellular processes upon deletion or
inhibition of MMPs can be observed in animal models and in
isolated cardiomyocytes. These results raise the question of
how such an intracellular activation can be achieved by extra-
cellular matrix remodeling enzymes. Two possible explana-
tions are conceivable: (i) MMPs act via extracellular modula-
tion that is transferred into the cell or (ii) MMPs possess a
direct intercellular action, because they are located at nearly
all intracellular structures in cardiomyocytes, i.e., at the
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sarcomer [43], in the nucleus [44], in mitochondria [45],
caveolae-bound [46], and in the cytosol [47].
The extracellular action of MMPs can modulate cell sur-
face receptors on cardiomyocytes that transfer information
into the cell. ADAM22, for example, interacts with integrin-
linked kinase which targets PI3K [48]. Loss of ADAM12 or
17 mediated cardiac hypertrophy via increased integrin B1
levels that result in overactivation of integrin-FAK signaling.
FAK (Focal adhesion kinase) directly associates and activates
PI3K and induces hypertrophic signaling via this pathway
[49]. Also we identified involvement of PI3K and ERK in
hype r t roph ic growth unde r MMP inh ib i t ion in
cardiomyocytes. However, in our study, an increased expres-
sion of integrin1βwas not observed underMMP inhibition by
TAPI-0 or ARP-100. Therefore, the integrin pathway found in
ADAM knockout mice, which acts via modulation of the ex-
tracellular surface of cardiomyocytes, may not be responsible
for hypertrophic growth effects under MMP inhibition in
cardiomyocyte.
Thus, the second possibility of MMP action, namely,
a direct intracellular action mechanism, may be respon-
sible for the hypertrophic action under MMP inhibition.
As already mentioned above, MMPs are found localized
in cardiomyocytes at sarcomeric structures, the nucleus,
and mitochondria and may thus directly repress hyper-
trophic signaling in the cell. However, up to now there
are no studies that presented evidence for the involve-
ment of intracellular localized MMPs in hypertrophic
growth.
In conclusion, MMPs found in cardiomyocyte culture
may act as repressor of cardiomyocyte hypertrophy
under baseline conditions. Active forms of MMPs are
expressed in cardiomyocytes, and inhibition of them
promotes hypertrophic growth via ERK and PI3K-
GSK3β signaling (Fig. 10). Thus, here we characterized
a new aspect of MMP function in cardiomyocytes.
Therefore, MMPs in the healthy heart may be important
players to repress cardiac hypertrophy.
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Fig. 10 Proposed signaling
pathway under MMP inhibition.
Inhibitors used for dissection of
the pathway are indicated in red
rectangles. The pathway via Akt
and GSK3 beta is assumed due to
the activation/inhibition of these
molecules under MMP inhibition
combined with the knowledge
that PI3K can signal via these
pathways, as outlined in the
discussion
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